In Search Of A Stimulant Use Disorder Treatment: ‘We’ve Been Doing It Wrong’
Executive Summary
US FDA official questions whether problem is due to population selection, outcome measures, or study duration. Potential endpoints include change in disease status as measured by DSM-5 criteria, cognitive function and quality of life, experts say.
You may also be interested in...
Califf Hints At Labeling Changes For Opioids And Chronic Pain
Califf also said the agency is open to endpoints other than abstinence for new opioid use disorder treatments at the fourth annual NIH HEAL Initiative Investigator Meeting.
‘Opioids’ Is Missing From The US FDA’s Overdose Prevention Framework Title On Purpose
Unlike prior plans, the FDA’s new substance abuse framework is intended to deal with stimulant and benzodiazepine use disorders, in addition to opioid abuse.
US FDA Elevates Controlled Substances Coordinator To New Deputy CDER Director Role
The move should increase the visibility of the FDA’s wide-ranging, and widely criticized, opioid epidemic response.